Brokers Issue Forecasts for Cabaletta Bio FY2030 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Equities researchers at HC Wainwright dropped their FY2030 EPS estimates for Cabaletta Bio in a note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $0.87 per share for the year, down from their prior forecast of $0.89. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($1.29) per share.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04.

Other analysts have also recently issued reports about the stock. Wells Fargo & Company decreased their price target on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 14th. TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a report on Monday, August 24th. Citigroup cut their price objective on Cabaletta Bio to $8.00 and set a “buy” rating on the stock in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. Finally, Wall Street Zen raised Cabaletta Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Cabaletta Bio Price Performance

Shares of CABA stock opened at $1.50 on Monday. The company’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $2.82. Cabaletta Bio has a 52 week low of $1.18 and a 52 week high of $4.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. StoneX Group Inc. purchased a new stake in Cabaletta Bio during the 3rd quarter worth $26,000. Kestra Advisory Services LLC acquired a new position in Cabaletta Bio in the 1st quarter worth $32,000. SummitTX Capital L.P. acquired a new position in Cabaletta Bio in the 1st quarter worth $34,000. Legal & General Group Plc purchased a new position in Cabaletta Bio in the 2nd quarter valued at about $34,000. Finally, HighTower Advisors LLC purchased a new position in Cabaletta Bio in the 2nd quarter valued at about $34,000.

About Cabaletta Bio

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.